Mirae Asset Global Investments Co. Ltd. Has $2.14 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Mirae Asset Global Investments Co. Ltd. raised its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 268.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 212,902 shares of the company's stock after acquiring an additional 155,196 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.16% of Vir Biotechnology worth $2,142,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Vir Biotechnology by 9.4% during the third quarter. Vanguard Group Inc. now owns 11,200,666 shares of the company's stock worth $104,950,000 after buying an additional 960,302 shares during the period. State Street Corp boosted its position in shares of Vir Biotechnology by 5.6% during the third quarter. State Street Corp now owns 5,830,417 shares of the company's stock worth $112,410,000 after buying an additional 311,279 shares during the period. BlackRock Inc. boosted its position in shares of Vir Biotechnology by 1.7% during the first quarter. BlackRock Inc. now owns 5,396,184 shares of the company's stock worth $138,790,000 after buying an additional 88,135 shares during the period. Alliancebernstein L.P. lifted its position in Vir Biotechnology by 0.8% in the fourth quarter. Alliancebernstein L.P. now owns 2,353,859 shares of the company's stock worth $59,576,000 after purchasing an additional 19,541 shares during the period. Finally, Geode Capital Management LLC lifted its position in Vir Biotechnology by 10.8% in the second quarter. Geode Capital Management LLC now owns 1,690,777 shares of the company's stock worth $41,475,000 after purchasing an additional 165,359 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Ann M. Hanly sold 2,711 shares of the company's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $10.05, for a total value of $27,245.55. Following the completion of the sale, the executive vice president now directly owns 132,069 shares in the company, valued at $1,327,293.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Ann M. Hanly sold 2,711 shares of the company's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $10.05, for a total value of $27,245.55. Following the completion of the sale, the executive vice president now directly owns 132,069 shares in the company, valued at $1,327,293.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Backer Marianne De sold 72,995 shares of the company's stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total transaction of $690,532.70. Following the sale, the chief executive officer now owns 678,457 shares of the company's stock, valued at $6,418,203.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 152,831 shares of company stock worth $1,525,844. Corporate insiders own 18.10% of the company's stock.

Vir Biotechnology Stock Down 0.1 %

Shares of Vir Biotechnology stock traded down $0.01 on Friday, hitting $7.95. 1,079,678 shares of the company traded hands, compared to its average volume of 730,346. The company has a 50-day moving average price of $10.12 and a 200 day moving average price of $9.62. Vir Biotechnology, Inc. has a 12-month low of $7.72 and a 12-month high of $27.48. The company has a market cap of $1.07 billion, a PE ratio of -1.73 and a beta of 0.41.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.28. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The business had revenue of $16.80 million for the quarter, compared to analysts' expectations of $11.18 million. During the same period in the previous year, the company posted ($0.76) EPS. Vir Biotechnology's revenue was down 66.0% on a year-over-year basis. Equities research analysts anticipate that Vir Biotechnology, Inc. will post -4.04 EPS for the current year.

Wall Street Analysts Forecast Growth

VIR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their target price on Vir Biotechnology from $9.00 to $10.00 and gave the stock a "neutral" rating in a research report on Friday, February 23rd. HC Wainwright restated a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, March 15th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.38.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.